|drug83||AMA Acknowledgement Drug Pricing Wiki||1.00|
|drug178||African American Sender Acknowledgement Wiki||1.00|
|drug179||African American Sender in Informational Videos. Wiki||1.00|
|drug2521||Placebo videos Wiki||1.00|
|drug146||Acknowledgement Racial Injustice AMA Wiki||1.00|
|drug2173||No Racial Inequality Highlighting Wiki||1.00|
|drug2733||Racial Inequality Highlighted Wiki||1.00|
|drug3610||White Sender in Acknowledgement Wiki||1.00|
|drug3611||White Sender in Informational Videos Wiki||1.00|
There is one clinical trial.
Ultomiris (Ravulizumab), is a monoclonal antibody that specifically targets terminal complement products and is proposed for the treatment of COVID-19 induced microvasculature injury and endothelial damage leading to thrombotic microangiopathy (TMA) causing acute kidney injury (AKI). Ravulizumab is to be used for participants with a confirmed diagnosis of COVID-19 who clinically or diagnostically present with deteriorating renal function. Ravulizumab causes immediate and sustained inhibition of the terminal complement cascade. The use of ravulizumab could ameliorate COVID-19 induced kidney injury due to TMA, shorten hospital stay, and improve the overall survival.
Description: 50% improvement in estimated glomerular filtration rate compared to conventional therapy within 30 days of treatment for COVID-19-induced acute kidney injury.Measure: Assess the efficacy of ravulizumab to ameliorate SARS-CoV-2 (COVID-19)-induced acute kidney injury manifesting as thrombotic microangiopathy. Time: 30 days
Description: Evaluation of pharmacokinetics of ravulizumab in participants with COVID-19 Changes in ravulizumab concentration in plasmaMeasure: Evaluation of pharmacokinetics of ravulizumab in participants with COVID-19 Time: 120 days
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports